CompletedPhase 1NCT03177395
PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Studying Autoimmune pulmonary alveolar proteinosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Egetis Therapeutics
- Principal Investigator
- James DearUniversity of Edinburgh
- Intervention
- PP100-01 (calmangafodipir)(drug)
- Enrollment
- 24 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2017 – 2018
Study locations (1)
- Royal Infirmary of Edinburgh, Edinburgh, City Of Edinburgh, United Kingdom
Collaborators
University of Edinburgh · NHS Lothian
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03177395 on ClinicalTrials.govOther trials for Autoimmune pulmonary alveolar proteinosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06431776Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).Savara Inc.
- RECRUITINGPHASE4NCT07200544Meloxicam in Mohs Micrographic SurgeryUniversity of Oklahoma
- RECRUITINGPHASE4NCT07102641Post-cesarean Analgesia: Comparing Effectiveness of Staggered v. Simultaneous TherapiesThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT06111846Study of Human Bone Marrow Mesenchymal Stem Cells in APAPJiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
- RECRUITINGPHASE4NCT05425355Intravenous vs Oral Acetaminophen in Postoperative Hip Fracture Adult PatientsUniversity Health Network, Toronto
- ACTIVE NOT RECRUITINGPHASE3NCT04544293Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)Savara Inc.
- RECRUITINGPHASE4NCT03759028Supracondylar Post-Operative Pain StudyUniversity of California, Los Angeles
See all trials for Autoimmune pulmonary alveolar proteinosis →